AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 112 min read$TXMD

TherapeuticsMD, Inc. (TXMD): Results of Operations and Financial Condition

TherapeuticsMD, Inc. (TXMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE TherapeuticsMD Announces Second Quarter 2026 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)—August 11, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties,

Original reporting
SEC EDGAR 8-K
Published Aug 11, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TXMD
Neutral
medium confidence
Mentioned
$TXMD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TXMDNeutralMed
01

Why it matters

The disclosure can reset near-term expectations for TXMD’s operating performance and financial condition, influencing valuation and risk appetite for the name.

02

Market read

A new quarterly results filing is released for TXMD, which can drive trading as investors digest the underlying financial and balance-sheet details in the attached press release.

03

What to watch

Traders will likely focus on cash burn, liquidity, and any changes in outlook, but those details are not present in the scraped excerpt.

Relevance 7/10Novelty 6/10Timing: Filed after the close, for immediate pre-market positioning around the Q2 2026 results reaction.

Background

The company submitted an SEC Form 8-K (Item 2.02) incorporating a press release announcing financial results for the quarter ended June 30, 2026 (Exhibit 99.1).

Company-level read

Ticker impact

$TXMDNeutralMedium confidence
Context

TherapeuticsMD filed an 8-K with its Q2 2026 results press release for the quarter ended June 30, 2026.

Expected impact

Potential near-term volatility around the market’s reaction to the Q2 2026 results and any disclosed balance-sheet or cash-flow details.

Evidence & confidence

The filing is a primary-source release of quarterly results (Item 2.02 via Exhibit 99.1). However, the scraped text does not include the actual financial figures, guidance, or key metrics, limiting precision on direction and magnitude.

Market effects

Sector

Limited spillover; this is company-specific financial reporting for a specialty therapeutics firm.

Regional

No clear regional contagion indicated by the filing text.

Global

No global macro or cross-border transaction disclosed in the provided content.

Counterpoint

What could challenge this read

If the market already priced in the quarter, the incremental impact may be muted despite the filing.

Key entities

  • company
    TherapeuticsMD, Inc.

    Subject of the 8-K, reporting Q2 2026 financial results via Exhibit 99.1.

  • filing
    SEC Form 8-K

    Regulatory filing used to furnish quarterly results under Item 2.02 and Regulation FD (Item 7.01).

Read at source← All news

Related articles

SEP 23
$PAYXHighAI 8/10

Paychex stock falls after fiscal Q1 results

Paychex (PAYX) shares fell 5.7% premarket after Q1 results. EPS beat estimates at $1.34, revenue hit $1.63B, up 6% YoY. Management Solutions revenue grew 4%, PEO and Insurance Solutions up 12%. Operating income rose 14% to $619.2M. FY2027 guidance maintained, with PEO revenue growth raised to 7-8%.

investing.com2 min
SEP 23
$PAYXHigh

Why is Paychex stock dropping today?

Paychex (PAYX) stock fell 5.7% in pre-market trading after reporting fiscal Q1 2027 results. The decline exceeded options market expectations, suggesting disappointment in earnings or guidance. The company missed consensus estimates of $1.32 EPS on $1.63B revenue. Analysts had mixed views, with price targets ranging from $111 to $150. The stock traded at $108, below its 52-week high of $130.32.

investing.com2 min
SEP 23
$AZOHighAI 8/10

AutoZone (AZO) Posts Strong Earnings, But Is the Stock Ready to Rebound?

AutoZone (AZO) reported Q4 2026 earnings with net sales up 5.6% YoY to $6.6B, operating profit up 10.1% to $1.3B, and EPS up to $56.05, beating expectations. Gross margin improved to 53.3%. The company opened 175 new stores, including 16 Mega Hubs. Management remains optimistic despite economic challenges. Shares rose 3.26% post-earnings but are down 30% over the past year. Analysts are mostly bullish with a median price target of $3,914.50, suggesting 35% upside.

insidermonkey.com2 min
SEP 23
$PAYXMedAI 8/10

PAYCHEX INC (PAYX): Results of Operations and Financial Condition

PAYCHEX INC (PAYX) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release 911 Panorama Trail South • Rochester, NY 14625 • paychex.com Paychex Reports First Quarter Fiscal 2027 Results • Delivered double-digit diluted EPS growth supported by strong PEO and Insurance Solutions revenue growth • Strong expansion of industry-leading operating

SEC EDGAR 8-K2 min
SEP 23
$WORHighAI 8/10

Why is Worthington Enterprises stock surging today?

Worthington Enterprises (WOR) stock rose 17% in pre-market trading after its fiscal Q1 2027 earnings beat estimates. Adjusted EPS was $0.82 vs. $0.75 expected, and net sales reached $343.9M, up 13% YoY. Free cash flow doubled to $54M, and the company repurchased $18.2M in shares. CEO Hayek cited growing demand for its data center cooling tanks as a growth driver. The S&P 500, Dow, and Nasdaq were down slightly in pre-market.

investing.com2 min